Tolinapant with or without oral decitabine/cedazuridine in relapsed/refractory peripheral T-cell lymphoma

Phase 2, randomised, open-label trial in peripheral T-cell lymphoma (PTCL) comparing Tolinapant + oral decitabine/cedazuridine with Oral decitabine/cedazuridine alone (2 arms). Primary endpoints: Incidence and severity of treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities and Overall response rate. Started Jan 2023; status: completed.